Use of florbetaben, a PET tracer, to detect beta-amyloid plaques in the brain may help doctors diagnose Alzheimer’s disease (AD) earlier, according to research to be presented as part of the emerging science program at the American Academy of Neurology’s 64 th annual meeting in New Orleans, April 21-28.
Clino, a venture by Tohoku University in Sendai, Japan, has entered into a research collaboration with GE Healthcare’s medical diagnostics division to discover in vivo imaging tracers for tau proteins that accumulate in the brains of patients with Alzheimer’s disease.
Atrophy of the corpus callosum (CC) is involved in early Alzheimer’s disease (AD) and can be detected in subjects with very mild dementia in the early stage of AD, according to a study published in the May issue of Academic Radiology.
On the heels of the FDA’s approval of Amyvid, Siemens Healthcare has applied for FDA 510(k) approval for syngo.PET Amyloid Plaque neurology quantification software. The software may be paired with Amyvid and Siemens biograph mCT PET/CT to comprise an integrated diagnostic imaging system for the detection of amyloid plaques in the living brain
Florbetapir F18 is an effective biomarker for Alzheimer’s disease (AD) pathology and has a wide effective dose range and high test—retest reliability, according to a study published in the March 1 issue of the Journal of Nuclear Medicine.
Researchers from Finland have developed a new tool for the objective diagnosis of Alzheimer’s disease which could allow for earlier diagnosis.
There may soon be an alternative to FDG-PET in the diagnosis of Alzheimer’s disease (AD) as the non-invasive arterial spin labeling (ASL) MRI method has been shown to provide comparable information, according to a study appearing in Neurology.
A new supplement to the Journal of Alzheimer’s Disease, “Imaging the Alzheimer Brain,” contains 31 papers that discuss the advances in imaging methodologies that are being used to understand, diagnose and treat Alzheimer’s disease.
Family history of Alzheimer disease (AD) is associated with several age-related changes that appear to influence AD biomarker abnormalities beyond the increased risk of the APOE4 gene, according to a report published in the October issue of Archives of Neurology. Previously, researchers suspected that AD has a lengthy preclinical period prior to the development of symptoms, in which cerebral lesions accumulate.
18F-FDG PET may provide a quantitative measure to detect progression from mild cognitive impairment (MCI) to Alzheimer's disease (AD), and could offer a mechanism to streamline clinical trials, according to a study published in this month's Journal of Nuclear Medicine.
PET imaging is showing a 7 percent average annual growth rate from 2008 to 2010, which is a decrease from the average annual rate of 10.4 percent from 2005 to 2008, according to IMV's research report, 2011 PET Market Summary Report.
Individuals with deterministic genes in whom it is known that Alzheimer’s disease (AD) will develop appear to show differences in beta-amyloid distribution when compared with non-dominantly inherited AD patients, helping to consolidate evidence that PET and MRI can depict brain changes well before the arrival of AD-related symptoms, according to preliminary findings presented July 20 at the 2011 Alzheimer’s Association International Conference in Paris.
Researchers continue to make headway in grasping the biological nature of Alzheimer’s disease, with a recent study discovering significant increases in the beta-amyloid uptake of florbetapir F18 as viewed on PET, published July 11 in the Archives of Neurology.
|
|
|
|
RSS 
